0.24
+0.0006(+0.25%)
Currency In USD
| Previous Close | 0.24 |
| Open | 0.25 |
| Day High | 0.25 |
| Day Low | 0.24 |
| 52-Week High | 1.73 |
| 52-Week Low | 0.22 |
| Volume | 213,920 |
| Average Volume | 1.09M |
| Market Cap | 4,228 |
| PE | -0.09 |
| EPS | -2.58 |
| Moving Average 50 Days | 0.28 |
| Moving Average 200 Days | 0.8 |
| Change | 0 |
If you invested $1000 in Akari Therapeutics, Plc (AKTX) 10 years ago, it would be worth $1.15 as of February 21, 2026 at a share price of $0.237. Whereas If you bought $1000 worth of Akari Therapeutics, Plc (AKTX) shares 5 years ago, it would be worth $3.17 as of February 21, 2026 at a share price of $0.237.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Akari Therapeutics to Present at the 2026 Biocom Global Partnering & Investor Conference
GlobeNewswire Inc.
Feb 18, 2026 2:05 PM GMT
In-person presentation on Wednesday, February 25th at 11:00 AM PT TAMPA, Fla. and LONDON, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with no
Akari Therapeutics Participates in Virtual Investor “What This Means” Interview Discussing the Company’s Expanded ADC Pipeline
GlobeNewswire Inc.
Feb 11, 2026 1:45 PM GMT
CEO Abizer Gaslightwala discusses the Company’s recent announcement around its ADC pipeline expansion and IP strategy Company also discusses its lead ADC program, AKTX-101, and its planned IND and CTA submissions as it advances towards first-in-human
Akari Therapeutics to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial
GlobeNewswire Inc.
Feb 05, 2026 2:15 PM GMT
– Live video webcast on Tuesday, February 10th at 1:00 PM EST TAMPA, Fla. and LONDON, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company pioneering next-generation antibody drug conjugates (A